New Study Reveals Key Role of Protein in Breast Cancer Progression

1 min read

In the intricate web of cancer biology, a new player has emerged: Jagged1. This Notch ligand has been found to regulate the extracellular matrix (ECM) deposition and remodeling in triple-negative breast cancer (TNBC). The ECM, long recognized as a key component of the tumor microenvironment, plays a critical role in driving cancer progression and treatment resistance.

Research has shown that high Jagged1 expression is associated with poor patient survival. When TNBC cells are cocultured with fibroblasts, Jagged1-mediated cross-talk between the two cell types leads to the activation of myofibroblasts, the accumulation of collagen in the ECM, and the alignment of ECM fibers. This process is regulated by transforming growth factor-β (TGFβ), a key signaling molecule involved in ECM remodeling.

The connection between Jagged1 and TGFβ is significant. In fibroblast cocultures, Jagged1 increases TGFβ activity, which in turn prevents the alignment of ECM fibers when inhibited. This suggests that Jagged1 regulates ECM remodeling upstream of TGFβ. Furthermore, research has found that higher substrate stiffness up-regulates Jagged1, creating a feed-forward loop between this Notch ligand, ECM stiffness, and TGFβ.

As we continue to explore the complexities of cancer biology, the discovery of Jagged1's role in regulating ECM deposition and remodeling offers new avenues for therapeutic investigation. The emergence of safe therapeutics targeting specific Notch components presents an opportunity to modulate Jagged1 and potentially treat invasive breast cancer. In this way, our understanding of the intricate relationships between cancer cells, fibroblasts, and the ECM expands, shedding light on the mechanisms driving tumor progression and treatment resistance.

1 min read

In the secret lives of tumors, a hidden world of cells and fibers is at work, shaping their growth and resistance to treatment. For triple-negative breast cancer patients, this hidden world can be particularly deadly.

At its core, this world revolves around a protein called Jagged1, which acts like a conductor in an orchestra of cells. When Jagged1 is expressed in high amounts, it orchestrates the formation of a new kind of cell - one that's more aggressive and invasive. This cell works closely with fibroblasts, a type of cell that provides structural support to tumors, to create a matrix of collagen fibers that helps the tumor grow and spread.

But why does this matter? Because understanding how Jagged1 controls this process could lead to new ways to treat triple-negative breast cancer. Researchers have discovered a key role for Jagged1 in regulating the growth of these aggressive cells, and by targeting this protein, they may be able to develop safer and more effective treatments that can help patients overcome their disease.

1 min read

In a tiny part of our bodies, something strange is happening that helps some cancers grow and spread. This happens when cells called fibroblasts start to talk to cancer cells, and they make each other stronger. It's like they're building a fortress around the cancer, making it harder for treatments to reach.

Imagine a big web made of threads, and the cancer cells are pulling on those threads, stretching them out and making them stronger. This is what happens when Jagged1, a special protein, helps build that web. Scientists found this by looking at how fibroblasts and cancer cells interact in the lab and in living animals. They discovered that when Jagged1 is turned up, it makes the web even stronger, which can help the cancer grow. This discovery might one day lead to new ways to treat cancers that are very hard to fight, like triple-negative breast cancer.